Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC2A4 regulator (SLC2A4RG) is a nuclear transcription factor that specifically regulates the expression of solute carrier family 2 member 4 (SLC2A4, encoding GLUT4), a key insulin-responsive glucose transporter[2][4][7][10]. SLC2A4RG binds to a defined consensus DNA sequence (5'-GCCGGCG-3') in the promoter of target genes, and can interact with other transcription factors such as myocyte enhancer factor 2 (MEF2), to induce or enhance gene transcription[2][4][7]. It is implicated in the regulation of GLUT4 expression in adipose and muscle tissues—central to whole-body glucose homeostasis—as well as in neuronal cells where it functions as a regulatory factor for genes involved in neurodegenerative disorders, particularly Huntington disease[4][7][10]. No direct drug targeting or clinical biomarkers specific to SLC2A4RG have been established. The gene is ubiquitously expressed, with higher levels in fat and kidney tissues[2].
Gene transcription activation through DNA binding Recruitment of transcriptional coactivators (e.g., MEF2) for SLC2A4 gene activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLC2A4 regulator (SLC2A4RG).